Trial Profile
Phase I, Randomized, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 579 in Healthy Adult Subjects and Patients With Stable Schizophrenia or Schizoaffective Disorder
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2012
Price :
$35
*
At a glance
- Drugs AMG 579 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 01 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Apr 2012 New trial record